Over the past week, shares of Intercept Pharmaceuticals Inc ICPT lost more than 7 percent of their value. Following such a decline, the Vetr crowd seems to believe some room for upside has been unlocked, as evidenced by its average price target of $147.31, which implies a potential return of 4.35 percent.
Related Link: Here's How Crowdsourced Ratings Can Beat The Market
Seeking to better reflect this upside potential, the community decided to upgrade its rating on the stock on Friday, from 3.0 Stars (Hold) to 3.5 Stars (Buy) - out of a possible 5.0 Stars rating.
Also in accordance with the rating and price target, 60 percent of the crowd's ratings are bullish.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
